ISRCTN ISRCTN31493512
DOI https://doi.org/10.1186/ISRCTN31493512
Secondary identifying numbers 1
Submission date
22/12/2016
Registration date
24/03/2017
Last edited
26/04/2022
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Current plain English summary as of 26/04/2022:

Background and study aims:
Type 2 diabetes mellitus (T2DM) is a long term condition where a person is unable to control their blood sugar (glucose) levels as they do not produce enough insulin to function properly (insulin deficiency), or that the body’s cells don’t react to insulin as they should do (insulin resistance). T2DM is a multi-factorial disease, meaning that it is associated with the effects of multiple genes in combination with lifestyle and environmental factors. The aim of this study is to look at the prevalence (commoness) and risk factors of impaired glucose metabolism (sugar breakdown) and diabetes in the general population.

Who can participate?
Men and women, aged between 40 and 65 years, registered at the municipal population registry of Hoorn.

What does the study involve?
In the year 2006, participants are asked to join the cohort (collection of participants). In the past 15 years, they visit the study centre four times, whilst being actively followed up for vital status by linking with the municipality register and for occurrence of long-term diseases. When they visit the centre, participants have a number of blood and urine samples taken to assess their blood sugar control, are weighted and measured, and fill out several questionnaires.

What are the possible benefits and risks of participating?
There are no notable benefits of participating. There is a small risk of pain and bruising following blood tests.

Where is the study run from?
The Diabetes Care and research Center in Hoorn (Netherlands)

When is study starting and how long is it expected to run for?
January 2006 to January 2050

Who is funding the study?
Amsterdam UMC, VU University Medical Center (Netherlands)

Who is the main contact?
1. Prof Joline Beulens (scientific)
j.beulens@amsterdamumc.nl
2. Dr Femke Rutters (scientific)
f.rutters@amsterdamumc.nl

______

Previous plain English summary:

Background and study aims:
Type 2 diabetes mellitus (T2DM) is a long term condition where a person is unable to control their blood sugar (glucose) levels as they do not produce enough insulin to function properly (insulin deficiency), or that the body’s cells don’t react to insulin as they should do (insulin resistance). T2DM is a multi-factorial disease, meaning that it is associated with the effects of multiple genes in combination with lifestyle and environmental factors. The aim of this study is to look at the prevalence (commoness) and risk factors of impaired glucose metabolism (sugar breakdown) and diabetes in the general population.

Who can participate?
Men and women, aged between 40 and 65 years, registered at the municipal population registry of Hoorn.

What does the study involve?
In the year 2006, participants are asked to join the cohort (collection of participants). In the past 10 years, they visit the study centre three times, whilst being actively followed up for vital status by linking with the municipality register and for occurrence of long-term diseases. When they visit the centre, participants have a number of blood and urine samples taken to assess their blood sugar control, are weighted and measured, and fill out several questionnaires.

What are the possible benefits and risks of participating?
There are no notable benefits of participating. There is a small risk of pain and bruising following blood tests.

Where is the study run from?
The Diabetes Care and research Center in Hoorn (Netherlands)

When is study starting and how long is it expected to run for?
January 2006 to January 2050

Who is funding the study?
VU University Medical Center (Netherlands)

Who is the main contact?
1. Dr Joline Beulens (scientific)
j.beulens@vumc.nl
2. Dr Femke Rutters (scientific)
f.rutters@vumc.nl

Contact information

Prof Joline Beulens
Scientific

VU University Medical Center
De Boelelaan 1089a
Amsterdam
1081HV
Netherlands

Phone +31 20 4445860
Email j.beulens@vumc.nl
Dr Femke Rutters
Scientific

VU University Medical Center
De Boelelaan 1089a
Amsterdam
1081HV
Netherlands

Phone +31 20 4445860
Email f.rutters@vumc.nl

Study information

Study designObservational prospective cohort study
Primary study designObservational
Secondary study designLongitudinal study
Study setting(s)Community
Study typeOther
Participant information sheet No participant information sheet available
Scientific titleA population-based study on glucose tolerance: the New Hoorn Study
Study hypothesisThe aim of this study is to investigate whether the increasing rates of longevity, physical inactivity and obesity affected the prevalence and risk factors of disturbances in glucose metabolism.
Ethics approval(s)Medical Ethics Committee of the VU University Medical Center Amsterdam, 11/05/2006, ref: 2006/93
ConditionType 2 diabetes
InterventionCurrent interventions as of 26/04/2022:

Participants are enrolled from the Hoorn study, a population-based survey carried out in the city of Hoorn between 2006-2007. The first visit takes place in 2006-2007. In a subgroup, around 250 participants a follow up visit takes place after three years. The third and fourth visit take place 8 and 15 years after baseline in the entire cohort.

For each visit, participants are requested to refrain from eating and drinking (except water) from 8:00 P.M. the night before the visit and from drinking alcohol from 5:00 P.M. the day before the visit. They are instructed to follow their usual diet the day before each visit and to be consistent in their diet (both in content and in approximate timing of evening meals and snacks) and physical activities on the pre-visit days. In addition, participants are requested not to smoke on the morning of the visit and not to come by bicycle. Participants do not follow these instructions will be asked to reschedule the visit. Upon arrival at the Diabetes Research Center, written informed consent is obtained. During the visit, height and weight are measured without shoes and heavy clothes. Waist circumference, hip circumference and blood pressure is measured. Fasting whole blood glucose from a capillary vein in the finger was determined on the spot. In participants with a fasting whole blood glucose level <10 mmol/l, a standard 75-g OGTT is performed. Venous blood samples are drawn before and 120 min after glucose ingestion. Finally, participants fill out questionnaires on lifestyle, medication, disease and SES. During the visit three years after baseline, microvascular function will be determined using capillary videomicroscopy of the dorsal skin of the nail fold.

_____

Previous interventions:

Participants are enrolled from the Hoorn study, a population-based survey carried out in the city of Hoorn between 2006-2007. The first visit takes place in 2006-2007. In a subgroup, around 250 participants a follow up visit takes place after three years. The third visit takes place 8 years after baseline in the entire cohort.

For each visit, participants are requested to refrain from eating and drinking (except water) from 8:00 P.M. the night before the visit and from drinking alcohol from 5:00 P.M. the day before the visit. They are instructed to follow their usual diet the day before each visit and to be consistent in their diet (both in content and in approximate timing of evening meals and snacks) and physical activities on the pre-visit days. In addition, participants are requested not to smoke on the morning of the visit and not to come by bicycle. Participants do not follow these instructions will be asked to reschedule the visit. Upon arrival at the Diabetes Research Center, written informed consent is obtained. During the visit, height and weight are measured without shoes and heavy clothes. Waist circumference, hip circumference and blood pressure is measured. Fasting whole blood glucose from a capillary vein in the finger was determined on the spot. In participants with a fasting whole blood glucose level <10 mmol/l, a standard 75-g OGTT is performed. Venous blood samples are drawn before and 120 min after glucose ingestion. Finally, participants fill out questionnaires on lifestyle, medication, disease and SES. During the visit three years after baseline, microvascular function will be determined using capillary videomicroscopy of the dorsal skin of the nail fold.
Intervention typeBehavioural
Primary outcome measureCurrent primary outcome measure as of 26/04/2022:

Disturbances in glucose metabolism is measured by fasting plasma glucose, 75-g Oral Glucose Tolerance Test and HbA1c at baseline and at the three follow-up measurements in 2010-2011 and 2013-2015 and 2021-2023.

_____

Previous primary outcome measure:

Disturbances in glucose metabolism is measured by fasting plasma glucose, 75-g Oral Glucose Tolerance Test and HbA1c at baseline and at the two follow-up measurements in 2010-2011 and 2013-2015.
Secondary outcome measures1. Depressive symptoms are measured using CES-D questionnaire at baseline and 7 year follow up
2. Quality of life is measured using questionnaires at baseline and 7 year follow up
3. Cardiovascular complications of diabetes are measured by a check of the medical records of the participants every three years
Overall study start date01/12/2005
Overall study end date01/01/2050

Eligibility

Participant type(s)All
Age groupAdult
SexBoth
Target number of participants2807
Participant inclusion criteria1. Men and women
2. Aged 40-65 years
3. From the municipal registry in the city of Hoorn
Participant exclusion criteriaNo exclusion criteria
Recruitment start date13/07/2006
Recruitment end date01/11/2007

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Diabetes Zorgsysteem locatie Hoorn
Maelsonstraat 7
Hoorn
1624 NP
Netherlands

Sponsor information

VU University Medical Center
University/education

De Boelelaan 1089a
Amsterdam
1081HV
Netherlands

Phone + 31 20 4445860
Email j.beulens@vumc.nl
ROR logo "ROR" https://ror.org/00q6h8f30

Funders

Funder type

Hospital/treatment centre

VU University Medical Center of Amsterdam

No information available

Novartis Pharma B.V

No information available

the European Union

No information available

the Innovative Medicine Initiative

No information available

Results and Publications

Intention to publish date01/01/2051
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Prof Joline Beulens (hoornstudy@vumc.nl)

Editorial Notes

26/04/2022: The following changes were made to the trial record:
1. The interventions were changed.
2. The primary outcome measure was changed.
3. The plain English summary was updated to reflect these changes.
10/08/2017: Internal review.